Development of hyperkalemia following treatment with dapagliflozin (DAPA) in a patient with type 2 diabetes after bilateral adrenalectomy

Dapagliflozin (DAPA), a sodium–glucose co-transporter 2 (SGLT2) inhibitor, is known to have a beneficial diuretic effect, in addition to a glucose-lowering effect. Although SGLT2 inhibitor has been reported, the increase of hyperkalemia in patients treated with renin–angiotensin–aldosterone system (...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CEN Case Rep
Hlavní autoři: Miyaoka, Daichi, Tsuda, Akihiro, Hayashi, Noriyuki, Toi, Norikazu, Yamasaki, Akiyo, Nagata, Yuki, Nakatani, Shinya, Kurajoh, Masafumi, Yamada, Shinsuke, Morioka, Tomoaki, Imanishi, Yasuo, Emoto, Masanori, Inaba, Masaaki
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Japan 2017
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5886918/
https://ncbi.nlm.nih.gov/pubmed/29134558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13730-017-0286-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky